{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:45:57Z","timestamp":1781664357902,"version":"3.54.5"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032128","name":"Taiho Oncology Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032128","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide, with increasing incidence in the US. Improvements in disease management and the increasing incidence of patients with metastatic CRC (mCRC) at younger ages has resulted in more patients being treated in the third-line setting. Treatment has evolved beyond chemotherapy with the approval of newer agents, but there is no consensus on the optimized choice or sequencing post second-line treatment. Identification of the drivers of treatment decisions may provide evidence to guide decision-making, ensuring that patients receive optimal care. The objective of this study was to evaluate treatment preferences and prescribing patterns for third-line mCRC among community-based physicians.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study surveyed community-based physicians in the US who were actively treating patients with mCRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall survival (OS) and impacts to patient quality of life (QoL) were primary considerations for any third-line treatment for mCRC. Physicians considered OS and progression-free survival (PFS) as extremely important factors when making third-line treatment decisions. Most physicians selected trifluridine-tipiracil (FTD-TPI) combined with bevacizumab as their first treatment choice for third-line mCRC (60%), compared to regorafenib (12%), FTD-TPI monotherapy (8%), capecitabine (8%), and fruquintinib (6%). Physicians identified fatigue, neutropenia, and hand-foot syndrome as the most challenging adverse events (AEs) to manage, while hand-foot syndrome and allergic reactions were AEs that would most likely lead physicians to discontinue treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings highlight the third-line treatment preferences and prescribing patterns of community-based physicians who are actively treating patients with mCRC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag018","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T12:48:22Z","timestamp":1770209302000},"source":"Crossref","is-referenced-by-count":1,"title":["Third-line treatment decision-making for metastatic colorectal cancer: a cross-sectional survey of US community physicians"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6960-6460","authenticated-orcid":false,"given":"Christopher","family":"Cann","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Fox Chase Cancer Center , Philadelphia, PA 19111,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Zhao","sequence":"additional","affiliation":[{"name":"Medical Affairs, Taiho Oncology, Inc , Princeton, NJ 08540,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem","family":"Khan","sequence":"additional","affiliation":[{"name":"Medical Affairs, Taiho Oncology, Inc , Princeton, NJ 08540,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2405-160X","authenticated-orcid":false,"given":"Malinda","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Clinical Research Group, Thermo Fisher Scientific , Waltham, MA 02451,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Taylor","sequence":"additional","affiliation":[{"name":"Clinical Research Group, Thermo Fisher Scientific , Waltham, MA 02451,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tehseen","family":"Salimi","sequence":"additional","affiliation":[{"name":"Medical Affairs, Taiho Oncology, Inc , Princeton, NJ 08540,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"2026021612221119100_oyag018-B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026021612221119100_oyag018-B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"2026021612221119100_oyag018-B3","author":"Surveillance, Epidemiology, and End Results (SEER)"},{"key":"2026021612221119100_oyag018-B4","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1136\/gutjnl-2019-319391","article-title":"Comparison of the \u00adincidence of colorectal cancer in young adults between the USA and Europe","volume":"69","author":"Wei","year":"2020","journal-title":"Gut"},{"key":"2026021612221119100_oyag018-B5","author":"National Cancer Institute"},{"key":"2026021612221119100_oyag018-B6","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.clcc.2017.03.019","article-title":"Treatment of patients with metastatic colorectal cancer in a real-world scenario: probability of receiving second and further lines of therapy and description of clinical benefit","volume":"16","author":"Tampellini","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"2026021612221119100_oyag018-B7","doi-asserted-by":"publisher","first-page":"104454","DOI":"10.1016\/j.critrevonc.2024.104454","article-title":"Third-line treatment and beyond in metastatic colorectal cancer: what do we have and what can we expect?","volume":"202","author":"Ayala-de Miguel","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026021612221119100_oyag018-B8","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.37765\/ajmc.2024.89545","article-title":"A decade of progress: advances in the third-line treatment of patients with metastatic colorectal cancer","volume":"30","author":"Bekaii-Saab","year":"2024","journal-title":"Am J Manag Care"},{"key":"2026021612221119100_oyag018-B9","doi-asserted-by":"publisher","author":"Barzi","year":".","DOI":"10.37765\/ajmc.2024.89546"},{"key":"2026021612221119100_oyag018-B10","doi-asserted-by":"publisher","first-page":"1269203","DOI":"10.3389\/fonc.2023.1269203","article-title":"Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis","volume":"13","author":"Gao","year":"2023","journal-title":"Front Oncol"},{"key":"2026021612221119100_oyag018-B11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.surg.2020.05.023","article-title":"Are academic hospitals better at treating metastatic colorectal cancer?","volume":"169","author":"Atallah","year":"2021","journal-title":"Surgery"},{"key":"2026021612221119100_oyag018-B12","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.amjsurg.2021.05.005","article-title":"Comparing outcomes for non-metastatic rectal cancer in academic vs. community centers: a propensity-matched analysis of the national cancer database","volume":"222","author":"Horsey","year":"2021","journal-title":"Am J Surg"},{"key":"2026021612221119100_oyag018-B13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061687","article-title":"Integrating academic and community practices in the management of colorectal cancer: the city of hope model","volume":"9","author":"Karimi","year":"2020","journal-title":"J Clin Med"},{"key":"2026021612221119100_oyag018-B14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.6004\/jnccn.2016.0088","article-title":"Value, access, and cost of cancer care delivery at academic cancer centers","volume":"14","author":"Nardi","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"2026021612221119100_oyag018-B15","author":"Florida Cancer Specialists & Research Institute","year":"2024"},{"key":"2026021612221119100_oyag018-B16","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s12094-023-03369-1","article-title":"Delphi consensus for the third-line treatment of metastatic colorectal cancer","volume":"26","author":"Garc\u00eda-Alfonso","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"2026021612221119100_oyag018-B17","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.3390\/curroncol28030194","article-title":"The screening and COnsensus based on practices and evidence (SCOPE) program-results of a survey on daily practice patterns for patients with mCRC","volume":"28","author":"Prager","year":"2021","journal-title":"Curr Oncol"},{"key":"2026021612221119100_oyag018-B18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.clcc.2024.12.002","article-title":"Impact of treatment with \u00adtrifluridine\/tipiracil in combination with bevacizumab on health-related quality of life and performance status in refractory metastatic colorectal cancer: an analysis of the phase III SUNLIGHT trial","volume":"24","author":"Taieb","year":"2025","journal-title":"Clin Colorectal Cancer"},{"key":"2026021612221119100_oyag018-B19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13561-025-00622-x","article-title":"Safety, efficacy, and cost-effectiveness evaluation of systemic treatments for refractory colorectal cancer: a systematic review and modeling study","volume":"15","author":"Zhao","year":"2025","journal-title":"Health Econ Rev"},{"key":"2026021612221119100_oyag018-B20","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-Tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021612221119100_oyag018-B21","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"2026021612221119100_oyag018-B22","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/s1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","volume":"20","author":"Bekaii-Saab","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026021612221119100_oyag018-B23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"key":"2026021612221119100_oyag018-B24","doi-asserted-by":"publisher","first-page":"e240084","DOI":"10.57264\/cer-2024-0084","article-title":"Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US","volume":"13","author":"Paly","year":"2024","journal-title":"J Comp Eff Res"},{"key":"2026021612221119100_oyag018-B25","doi-asserted-by":"publisher","first-page":"1502185","DOI":"10.3389\/fonc.2024.1502185","article-title":"Trifluridine\/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion","volume":"14","author":"Pinto","year":"2024","journal-title":"Front Oncol"},{"key":"2026021612221119100_oyag018-B26","doi-asserted-by":"publisher","first-page":"1606091","DOI":"10.3389\/ijph.2023.1606091","article-title":"Real-world utilization, barriers, and factors associated with the targeted treatment of metastatic colorectal cancer patients in China: a multi-center, hospital-based survey study","volume":"68","author":"Liu","year":"2023","journal-title":"Int J Public Health"},{"key":"2026021612221119100_oyag018-B27","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.2217\/fon-2023-0020","article-title":"Drivers of physician decision-making and patient perspectives across lines of therapy in multiple myeloma in the USA","volume":"19","author":"Ribbands","year":"2023","journal-title":"Future Oncol"},{"key":"2026021612221119100_oyag018-B28","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/oncolo\/oyad267","article-title":"Evaluating oncologists\u2019 practice patterns and decision-making in locally advanced or metastatic urothelial carcinoma: the US physician PARADIGM study","volume":"29","author":"Gupta","year":"2024","journal-title":"Oncologist"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag018\/66799632\/oyag018.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyag018\/66799632\/oyag018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyag018\/66799632\/oyag018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:22:18Z","timestamp":1771262538000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag018\/8466439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag018","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,5]]},"article-number":"oyag018"}}